✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Glucagonis the generic ingredient in five branded drugs marketed by Amphastar Pharms Inc, Lilly, Eli Lilly And Co, Xeris, Novo Nordisk, and Fresenius Kabi Usa, and is included in seven NDAs. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.
Glucagon has one hundred and four patent family members in forty-two countries.
There are twelve drug master file entries for glucagon. Three suppliers are listed for this compound.
Summary for glucagon
|Drug Master File Entries:||12|
|Finished Product Suppliers / Packagers:||3|
|Raw Ingredient (Bulk) Api Vendors:||24|
|Formulation / Manufacturing:||see details|
|Drug Prices:||Drug price trends for glucagon|
|What excipients (inactive ingredients) are in glucagon?||glucagon excipients list|
|DailyMed Link:||glucagon at DailyMed|
Recent Clinical Trials for glucagon
Identify potential brand extensions & 505(b)(2) entrants
|AZ Delta||Phase 3|
|Jessa Hospital||Phase 3|
Pharmacology for glucagon
|Drug Class||Antihypoglycemic Agent |
Gastrointestinal Motility Inhibitor
|Physiological Effect|| Decreased GI Motility |
Decreased GI Smooth Muscle Tone
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Xeris||GVOKE PFS||glucagon||SOLUTION;SUBCUTANEOUS||212097-001||Sep 10, 2019||RX||Yes||Yes||See Plans and Pricing||See Plans and Pricing||Y||See Plans and Pricing|
|Novo Nordisk||GLUCAGEN||glucagon hydrochloride||INJECTABLE;INJECTION||020918-001||Jun 22, 1998||RX||Yes||Yes||See Plans and Pricing||See Plans and Pricing||See Plans and Pricing|
|Xeris||GVOKE HYPOPEN||glucagon||SOLUTION;SUBCUTANEOUS||212097-004||Sep 10, 2019||RX||Yes||Yes||See Plans and Pricing||See Plans and Pricing||Y||See Plans and Pricing|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||Patent No.||Patent Expiration|
|Eli Lilly And Co||BAQSIMI||glucagon||POWDER;NASAL||210134-001||Jul 24, 2019||See Plans and Pricing||See Plans and Pricing|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>Patent No.||>Patent Expiration|
|Company||Drugname||Inn||Product Number / Indication||Status||Generic||Biosimilar||Orphan||Marketing Authorisation||Marketing Refusal|
|Tetris Pharma B.V||Ogluo||glucagon||EMEA/H/C/005391
Ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.
|Eli Lilly Nederland B.V.||Baqsimi||glucagon||EMEA/H/C/003848
Baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus.
|>Company||>Drugname||>Inn||>Product Number / Indication||>Status||>Generic||>Biosimilar||>Orphan||>Marketing Authorisation||>Marketing Refusal|
|Country||Patent Number||Title||Estimated Expiration|
|Moldova, Republic of||3258919||See Plans and Pricing|
|South Korea||102121443||See Plans and Pricing|
|European Patent Office||3673899||FORMULATION DE POUDRE NASALE POUR LE TRAITEMENT DE L'HYPOGLYCÉMIE (NASAL POWDER FORMULATION FOR TREATMENT OF HYPOGLYCEMIA)||See Plans and Pricing|
|>Country||>Patent Number||>Title||>Estimated Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.